Literature DB >> 12160137

Lysosomal enzymes, cathepsins in brain tumour invasion.

Natasa Levicar1, Tadej Strojnik, Janko Kos, Ricardo A Dewey, Geoffrey J Pilkington, Tamara T Lah.   

Abstract

The expression patterns of different classes of peptidases in central nervous system (CNS) tumours have been most extensively studied in astrocytomas and meningiomas. Although the two types of tumours are very different in most respects, both may invade locally into normal brain. This process of invasion includes increased synthesis and secretion of lysosomal proteolytic enzymes - cathepsins. Aspartic endopeptidase cathepsin (Cat) D levels were found to be elevated in high-grade astrocytoma and partial inhibition of glioblastoma cell invasion by anti-Cat D antibody suggests that the enzyme activity is involved in the invasion process. Several studies on cysteine endopeptidase (CP) Cat B in gliomas agreed that transcript abundance, protein level and activity of Cat B increased in high-grade astrocytoma cultures compared with low-grade astrocytoma cultures and normal brain. Moreover, in glioma biopsies Cat B levels correlated with evidence of clinical invasion and it has been demonstrated that Cat B both in tumour cells and in endothelial cells can serve as a new biological marker for prognosis in glioblastoma patients. A high level of Cat B protein was also a diagnostic marker for invasive types of meningioma, distinguishing between histomorphologically benign, but invasive meningiomas and noninvasive, so-called clear-benign meningiomas. Cat L was also significantly increased in high-grade astrocytoma compared with low-grade astrocytoma and normal brain. Specific Cat L antibodies and antisense Cat L RNA transfection significantly lowered glioblastoma cell invasion. In meningioma, Cat L was a less-significant marker of invasion than Cat B. In contrast to cathepsins, the activities of endogenous cysteine peptidase inhibitors (CPIs), including stefins, cystatins and kininogens, were significantly higher in benign and atypical meningioma cell extracts than in malignant meningioma, and low-grade compared to high-grade astrocytoma. However, very low levels of stefins A and B were found in meningioma and glioblastoma tissues. Further studies on the expression levels and balance between cysteine endopeptidases (CPs) and CPIs would improve the clinical application of cathepsins in prognosis, which would lead to more-informed therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12160137     DOI: 10.1023/a:1015892911420

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  61 in total

1.  Overview--burgeoning promise in metastasis research.

Authors:  J A Wyke
Journal:  Eur J Cancer       Date:  2000-08       Impact factor: 9.162

2.  Stefins and lysosomal cathepsins B, L and D in human breast carcinoma.

Authors:  T T Lah; M Kokalj-Kunovar; B Strukelj; J Pungercar; D Barlic-Maganja; M Drobnic-Kosorok; L Kastelic; J Babnik; R Golouh; V Turk
Journal:  Int J Cancer       Date:  1992-01-02       Impact factor: 7.396

3.  Degradation of laminin by human tumor cathepsin B.

Authors:  T T Lah; M R Buck; K V Honn; J D Crissman; N C Rao; L A Liotta; B F Sloane
Journal:  Clin Exp Metastasis       Date:  1989 Jul-Aug       Impact factor: 5.150

4.  Activation of astrocytic lysosomal proteinases by factors released by mononuclear leukocytes.

Authors:  C T Bever; D S Snyder; R O Endres; K D Morgan; A Postlethwaite; J N Whitaker
Journal:  Neurochem Res       Date:  1989-01       Impact factor: 3.996

Review 5.  Molecular regulation, membrane association and secretion of tumor cathepsin B.

Authors:  B A Frosch; I Berquin; M R Emmert-Buck; K Moin; B F Sloane
Journal:  APMIS       Date:  1999-01       Impact factor: 3.205

Review 6.  Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview.

Authors:  H Rochefort; M Garcia; M Glondu; V Laurent; E Liaudet; J M Rey; P Roger
Journal:  Clin Chim Acta       Date:  2000-02-15       Impact factor: 3.786

7.  Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues.

Authors:  M R Buck; D G Karustis; N A Day; K V Honn; B F Sloane
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

8.  Cathepsin D gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells.

Authors:  V Cavaillès; P Augereau; H Rochefort
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

Review 9.  Proteases as prognostic markers in cancer.

Authors:  M J Duffy
Journal:  Clin Cancer Res       Date:  1996-04       Impact factor: 12.531

10.  Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene.

Authors:  B F Sloane; K Moin; M Sameni; L R Tait; J Rozhin; G Ziegler
Journal:  J Cell Sci       Date:  1994-02       Impact factor: 5.285

View more
  21 in total

1.  Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas.

Authors:  Maode Wang; Jianjian Tang; Shouxun Liu; Daizo Yoshida; Akira Teramoto
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

2.  Kinins in Glioblastoma Microenvironment.

Authors:  Mona N Oliveira; Barbara Breznik; Micheli M Pillat; Ricardo L Pereira; Henning Ulrich; Tamara T Lah
Journal:  Cancer Microenviron       Date:  2019-08-16

3.  The transglutaminase 2 gene is aberrantly hypermethylated in glioma.

Authors:  Lisa M Dyer; Kevin P Schooler; Lingbao Ai; Corinne Klop; Jingxin Qiu; Keith D Robertson; Kevin D Brown
Journal:  J Neurooncol       Date:  2010-07-03       Impact factor: 4.130

4.  Secretome signature of invasive glioblastoma multiforme.

Authors:  Catherine A Formolo; Russell Williams; Heather Gordish-Dressman; Tobey J MacDonald; Norman H Lee; Yetrib Hathout
Journal:  J Proteome Res       Date:  2011-05-31       Impact factor: 4.466

5.  Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells.

Authors:  Vineet Sangar; Cory C Funk; Ulrike Kusebauch; David S Campbell; Robert L Moritz; Nathan D Price
Journal:  Mol Cell Proteomics       Date:  2014-07-05       Impact factor: 5.911

6.  Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.

Authors:  Jingxin Qiu; Lingbao Ai; Cheppail Ramachandran; Bing Yao; Suhasni Gopalakrishnan; C Robert Fields; Amber L Delmas; Lisa M Dyer; Steven J Melnick; Anthony T Yachnis; Philip H Schwartz; Howard A Fine; Kevin D Brown; Keith D Robertson
Journal:  Lab Invest       Date:  2008-07-07       Impact factor: 5.662

7.  Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM).

Authors:  W J Lukiw; J G Cui; Y Y Li; F Culicchia
Journal:  J Neurooncol       Date:  2008-08-31       Impact factor: 4.130

8.  Inhibition of glioma cell lysosome exocytosis inhibits glioma invasion.

Authors:  Yu Liu; Yijiang Zhou; Keqing Zhu
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

9.  Role of endolysosomes and pH in the pathogenesis and treatment of glioblastoma.

Authors:  Peter Halcrow; Gaurav Datta; Joyce E Ohm; Mahmoud L Soliman; Xuesong Chen; Jonathan D Geiger
Journal:  Cancer Rep       Date:  2019-05-06

Review 10.  Proteases Regulate Cancer Stem Cell Properties and Remodel Their Microenvironment.

Authors:  Anamarija Habič; Metka Novak; Bernarda Majc; Tamara Lah Turnšek; Barbara Breznik
Journal:  J Histochem Cytochem       Date:  2021-07-26       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.